Abstract: OBJECTIVE To investigate cardiovascular internal medicine use of nitrate ester intravenous dosage form and to evaluate its rationality. METHODS Through the clinical medication decision support extraction from February 1, 2014 to September 30 patients with cardiovascular division was discharged. The medical records of 100 randomly selected in accordance with conditions, according to The Nitric Acid Ester Standardized Application in Cardiovascular Disease Expert Consensus and The Nitrate Drugs Intravenously Suggestions, indications, intravenous drug use, whether with isosorbide mononitrate zyban combination of statistics and the evaluation of the rationality. RESULTS From Feb to Sep in 2014, 5-ISMN-a total of 2 003 cases of vein, ISDN-a total of 45 cases, NTG-a total of 1 092 cases were incluede. A random sample of 100 using nitrates intravenous formulations of medical records, 82 cases combined utilization 5-ISMN sustained release tablet, combination is not reasonable. The average course of treatment were 8.5 d and 9.5 d. CONCLUSION From Feb to Sep in 2014, improper dosage form is selected of nitrate vein variety, intravenous formulations used in combination with oral sustained-release dosage form is not reasonable; intravenous medication treatment without the basis, without evaluation.